Skip to main content
Top

Breast Cancer Research and Treatment

Issue 2/2003

Content (7 Articles)

Patients with Recurrent Breast Cancer: Does the Primary Axillary Lymph node Status Predict more Aggressive Tumor Progression?

Brigitte Rack, Wolfgang Janni, Bernd Gerber, Barbara Strobl, Christian Schindlbeck, Elisabeth Klanner, Gerhard Rammel, Harald Sommer, Thomas Dimpfl, Klaus Friese

Studies of the Potential Utility of Ki67 as a Predictive Molecular Marker of Clinical Response in Primary Breast Cancer

L. Assersohn, J. Salter, T.J. Powles, R. A'hern, A. Makris, R.K. Gregory, J. Chang, M. Dowsett

Potent Killing of Paclitaxel- and Doxorubicin-resistant Breast Cancer Cells by Calphostin C Accompanied by Cytoplasmic Vacuolization

Baoqing Guo, Stacey L. Hembruff, David J. Villeneuve, Angie F. Kirwan, Amadeo M. Parissenti

Instructions for Authors

Instructions for Authors

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine